Replies to post #620992 on NorthWest Biotherapeutics Inc (NWBO)

[hoffmann6383]

My IT guru friend Ex! Can you explain to us how specials are paid? Do the funds go to Advent? Do the funds go to NWBO. If the funds go to Advent, how are they split from there?

I'll answer for you, no you can't explain this. This is not public information. Yet, this doesn't stop you from filling the void with the most negative narrative possible.

A quick reminder for those unfamiliar with Ex, the man who makes up facts to disparage NWBO.

exwannabe:

The CHECKMATE-548 trial has a very similar population to the methylated population of the DCVax-L P3

flipper:

The full checkmate 548 paper has not been published....is...devoid of specific relevant patient demographics.

[CrashOverride]

Net after R&D expenses. Perhaps some patients are getting a subsidy as the firm have further "real world" research they are doing while administering the vaccine? Maybe some of these patients are being used to validate Flaskworks?

As much as I thought we would see a large revenue increase under Specials that isn't the case. Though that shouldn't be a concern as the firm are funded through approvals.

Sawston has manufacturing capacity for 12K patients a year. Once we see MHRA approval this whole distraction will seem quite irrelevant!

[norisknorewards]

we don't need your IT For Dummies book

[sentiment_stocks]

First, wouldn't the net, in this case, be the part of the larger fee that comes to Northwest?

Second, if Northwest were offering a discounted rate, is it possible they are using those patients' data for something to do with the regulators?

[drugrunner]

Yes so simple even EX can lie about it